The meeting’s goal is to provide continuing medical education for neurosurgeons, neurosurgical residents in training, postgraduate neurosurgical fellows, and advanced practice providers such as nurses, physician assistants and clinical specialists. It’s an opportunity to engage with colleagues, members, and medical attendees, as well as build new connections in the process of discovering what we all have in common. This year’s theme is Neurosurgery Connected and will be attended by neurosurgical experts from around the world.
We invite you to stop by and visit our team at Booth #612 to learn more about what’s new at IMRIS.
Minneapolis, MN (September 22, 2022) – IMRIS, Deerfield Imaging, the global leader in intraoperative imaging, is pleased to announce the opening of the new iMRI 3T-V Surgical Theatre at Boston Children’s Hospital’s new Hale Family Building. This installation marks the second IMRIS suite purchased by Boston Children’s Hospital and will now replace their older system.
The new IMRIS Surgical Theatre at Boston Children’s Hospital Hale Family Building features a three-room configuration with a 3 Tesla high-field MR scanner that travels into the two operating rooms on demand.
Patient safety is raised and delays in the clinical workflow are decreased since the MRI is brought to the patient while the procedure is being performed rather than having to take the patient to the radiology department and back to the OR. Having access to real-time intraoperative MRI during surgeries can improve surgical precision.
“As we look at what it has done for us, the IMRIS System has changed the standard of care for pediatric brain tumor patients. We are able to see how much of the tumor has been removed while we are still in the operating room. This helps prevent second surgeries as well as additional anesthesia because the patients do not need to get a second scan the day after surgery.” said Dr. Mark Proctor, MD, Chairman of Neurosurgery, Boston Children’s Hospital.
The opening of the iMRI 3T-V Surgical Theatre is part of the ongoing commitment by Boston Children’s Hospital and IMRIS to provide the highest level of patient care through state-of-the-art technologies that assist in the diagnosis and treatment of pediatric neurological disorders. The new system utilizes Siemens BioMatrix 3T Technology that adapts to patient differences, reducing exam variations and re-scans while enhancing results.
“Boston Children’s Hospital was the first commercial IMRIS system installed in the United States, so it’s gratifying that they will now have the latest IMRIS intraoperative 3T MRI technology to benefit pediatric patients. IMRIS is proud to continue its support of Boston Children’s Hospital with the addition of our most advanced intraoperative imaging system. The recently opened 3T-V Surgical Theatre will enable clinicians to diagnose and treat complex neurological conditions in pediatric patients with a high level of precision and confidence throughout the procedure, changing the standard of care for the treatment of pediatric brain tumor patients.” said Marc Buntaine, CEO of IMRIS, Deerfield Imaging.
About IMRIS, Deerfield Imaging
As a leader in image-guided therapy solutions, IMRIS, Deerfield Imaging provides optimized fully integrated image-guided therapy environments that address the important needs of patients, clinicians, and hospitals by delivering timely information on surgical targets and results to clinicians for use during surgical or interventional procedures. The IMRIS Surgical Theatre enables intraoperative imaging directly within operating rooms. The Company also designs and manufactures proprietary head fixation devices, imaging coils, and OR tables for use in this unique and multifunctional intraoperative environment. IMRIS products are sold globally to clinical centers in the neurosurgical, spinal, cardiovascular, and orthopedic markets. For more information, please visit www.imris.com.
Minneapolis, MN (September 13, 2022) – IMRIS, Deerfield Imaging, the global leader in intraoperative MRI has announced the acquisition of Superconducting Systems, Inc. (SSI), Billerica, MA. SSI designs and develops cryogen-free (liquid helium free) superconducting magnets for medical and research applications. With funding by the U.S. National Institute of Health, SSI has been collaborating with research divisions of major Boston-area scientific institutions to demonstrate the viability and benefits of its cryogen-free systems. SSI magnets are used in commercial MRI systems throughout the world.
SSI CEO Dr. Shahin Pourrahimi stated “We are excited to become part of IMRIS and help develop innovative cryogen-free magnets that can power next generation point-of-care MRI systems. IMRIS provides development and commercialization expertise that will enable SSI magnets to offer clinical value in a number of medical applications where mid-field intra-procedural MRI can have significant impact on patient outcomes.”
IMRIS CEO Marc Buntaine further commented “IMRIS provides intraoperative MRI capabilities in neurosurgery with its surgical theaters, a multi-room suite in which the MRI can travel between operating and diagnostic rooms. The acquisition of SSI is another achievement in the continued growth of IMRIS. We are excited to integrate the highly innovative team and technology of SSI into the IMRIS family.”
About IMRIS, Deerfield Imaging
As a leader in image guidance solutions, IMRIS, Deerfield Imaging provides optimized, fully integrated image-guided therapy environments that address the important needs of patients, clinicians, and hospitals by delivering timely MRI and imaging data to clinicians for use during surgical or interventional procedures. The IMRIS Surgical Theatre enables intraoperative imaging directly within operating rooms. The Company also designs and manufactures proprietary head fixation devices, imaging coils and OR tables for use in this unique and multifunctional intraoperative environment. IMRIS products are sold globally to clinical centers in the neurosurgical, spinal, cardiovascular, and orthopedic markets. Over 70,000 patients have benefited from lifesaving or life-extending procedures performed in an IMRIS Surgical Theatre in the past 17 years. Additional information about IMRIS, Deerfield Imaging is available at www.imris.com.
Minneapolis, MN (April 28, 2022) – IMRIS, Deerfield Imaging, the global leader in intraoperative imaging suites for neurosurgery and related surgical indications, announced today a new partnership with Trinity Capital Inc. (NASDAQ: TRIN) (“Trinity”) for its latest capital raise. Trinity is a leading provider of debt and equipment financing to growth stage companies and has funded over $1.6 Billion across 186 companies.
“We are excited to partner with Trinity Capital in financing the next stage of our growth in intraoperative MRI surgical suites and related clinical products,” said Marc Buntaine, IMRIS’ Chief Executive Officer. “This partnership with Trinity is integral to unlocking our growth strategies in this dynamic market. We remain committed to delivering the world’s foremost neurosurgery intraoperative imaging suites, and now IMRIS is entering a new phase of growth, bringing new clinical value to our current and future customers and improving patient outcomes.”
Added Bob D’Acquisto, Managing Director of Trinity Capital, “We are excited about working with the team at IMRIS as they grow their core business to new levels of excellence. Along with being a leader in designing and installing intraoperative surgical suites, their team is also branching into new areas, bringing clinical value to their customers. We look forward to supporting them in this endeavor and being a part of their growth story.”
About IMRIS, Deerfield Imaging
IMRIS, Deerfield Imaging is the world leader in designing, installing, and supporting the most technically advanced neurosurgery intraoperative imaging suites. Complete with diagnostic and surgical dual application of MRI and other imaging modalities, IMRIS, with its “Moving Magnet” technology, provides the gold standard of hybrid imaging surgical suites installed in the world’s leading hospitals across the globe.
About Trinity Capital
Trinity Capital (Nasdaq: TRIN), an internally managed specialty lending company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended, is a leading provider of debt, including loans and equipment financing, to growth stage companies, including venture-backed companies and companies with institutional equity investors. Trinity Capital’s investment objective is to generate current income and, to a lesser extent, capital appreciation through investments consisting primarily of term loans and equipment financings and, to a lesser extent, working capital loans, equity and equity-related investments. Trinity Capital believes it is one of only a select group of specialty lenders that has the depth of knowledge, experience, and track record in lending to growth stage companies.
The American Association of Neurological Surgeons (AANS) is a scientific and educational association focused on advancing the specialty of neurological surgery. The AANS is dedicated to advancing the specialty of neurological surgery in order to provide the highest quality of neurosurgical care to the public. This year’s theme is The Culture of Neurosurgery and will be attended by neurosurgical experts from around the world.
We invite you to stop by and visit our team at Booth #1102 to see what’s new at IMRIS and how we can help you design and create your IMRIS Hybrid Operating Suite.
February 16-19, 2022, The Diplomat Beach Resort, Hollywood, Florida
The Southern Neurological Society (SNS), is the formal design of the neurological pioneer, Dr. R. Eustace Semmes. This year the society celebrates their 72nd year for neurosurgeons to engage in like-minded discussions of emerging techniques, best practices, and evidence-based medicine to enlighten and stimulate thoughts on how patients are treated now and in the future.
Come visit our team at booth #25 to learn more about the IMRIS hybrid operating suite experience!
Minneapolis, MN (October 13, 2021) – IMRIS, Deerfield Imaging, the global leader in intraoperative imaging, announced that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the new iMRI 3T-V Surgical System, a multifunctional surgical environment designed to deliver unmatched intraoperative vision for clinicians, assist in surgical decision-making and enhance precision in treatment.
This newest imaging technology, based on Siemens MAGNETOM Vida, provides improved imaging speed, image quality and efficiency of scan acquisition by minimizing motion artifacts and sedation/anesthesia times thus decreasing the time to results. The new system utilizes Siemens BioMatrix 3T Technology that adapts to patient differences, reducing exam variations and rescans while enhancing results.
The IMRIS iMRI 3T-V Surgical Theatre, which was FDA cleared with our patented magnet mover technology, is available in a two-room or three-room configuration and features a 3 Tesla high-field MR scanner that will travel into the operating room on demand. This will provide intraoperative images of diagnostic quality without moving the patient and thereby minimizing associated risks. Clinicians will have access to real-time information while optimal surgical access and techniques are preserved. With integrated tools and technology designed specifically for neurosurgical applications, the IMRIS Surgical Theatre will allow optimal patient positioning for use of intraoperative MRI. Once positioned, it is unlikely the patient will ever need to be moved for scanning – before, during or after a procedure. Our patented ceiling-mounted rail system, the IMRIS Magnet Mover, is truly a one-of-a-kind innovation.
About IMRIS, Deerfield Imaging
As a leader in image guided therapy solutions, IMRIS provides optimized fully integrated image-guided therapy environments that serve to address the important needs of patients, clinicians and hospitals by delivering timely information on surgical targets and results to clinicians for use during surgical or interventional procedures. The IMRIS Surgical Theatre incorporates MRI, CT and angiography into multi-purpose surgical suites to provide advanced intraoperative imaging directly in operating rooms. With a unique symphony of engineering and advanced imaging technology, the IMRIS Surgical Theatre is built for the human experience and inspired by the human mind – each IMRIS Surgical Theatre is custom-developed for the hospital and surgeons to uniquely compliment their workflow and intended use. IMRIS also designs and manufactures proprietary head fixation devices, imaging coils, and OR tables for use in this unique and multifunctional intraoperative environment. Products are sold globally to hospitals in the neurosurgical, spinal, cardiovascular, and orthopedic markets.
Minneapolis, MN (October 5, 2021) – IMRIS, Deerfield Imaging, the global leader in intraoperative imaging, is pleased to announce that its Board of Directors has appointed Marc R. Buntaine as Chief Executive Officer effective October 1, 2021.
With more than 20 years of experience in the Medical Capital Equipment industry, focusing on launching new technologies, Buntaine is a highly distinguished leader with a track record of successfully growing companies and market share through establishing long-term relationships with healthcare professionals and partners. He joins IMRIS with senior leadership experience as well as serving as CEO for several different high growth companies.
“Throughout his career in med-tech devices, Marc has pioneered a number of new technologies that have become state-of-the art approaches in neurosurgery and oncology practices, including stereotactic radiosurgery, image guided surgery, image guided radiotherapy, and intraoperative imaging. We are pleased to welcome Marc to IMRIS as we launch our newest Hybrid Intraoperative Imaging Suites,” said Dr. Gregory Sorensen, Executive Chairman.”
IMRIS has recently launched its newest surgical theatre, the iMRI 3T-V, a multifunctional surgical environment designed to deliver unmatched intraoperative vision for clinicians, assist in surgical-decision making and enhance precision in treatment.
“I am very excited to be joining IMRIS at this time of exceptional growth and increasing awareness of the powerful impact of bringing MRI into the operating theater,” added Marc Buntaine. “Recent clinical studies have demonstrated clear evidence of improved patient outcomes by utilizing MRI in the O.R.; it is truly exciting to join a company that is contributing toward better surgical outcomes.”
About IMRIS, Deerfield Imaging
As a leader in image guided therapy solutions, IMRIS provides optimized fully integrated image-guided therapy environments that serve to address the important needs of patients, clinicians and hospitals by delivering timely information on surgical targets and results to clinicians for use during surgical or interventional procedures. The IMRIS Surgical Theatre incorporates MRI, CT and angiography into multipurpose surgical suites to provide advanced intraoperative imaging directly in operating rooms. With a unique symphony of engineering and advanced imaging technology, the IMRIS Surgical Theatre is built for the human experience and inspired by the human mind – each surgical theatre is custom-developed for the hospital and surgeons to uniquely compliment their workflow and intended use. IMRIS also designs and manufactures proprietary head fixation devices, imaging coils, and OR tables for use in this unique and multifunctional intraoperative environment. Products are sold globally to hospitals in the neurosurgical, spinal, cardiovascular, and orthopedic markets.
